Immune Checkpoint Inhibitors in Lung Cancer – An Unheralded Opportunity?

Autor: Marshall, R. ^∗, Popple, A. ^∗, Kordbacheh, T. ^∗, Honeychurch, J. ^∗, Faivre-Finn, C. ^{∗, †}, Illidge, T. ^{∗, †}

Publikováno v: In Clinical Oncology April 2017 29(4):207-217

American Apocalypse: A History of Modern Evangelicalism Matthew Avery Sutton

Autor: Honeychurch, J. Robert

Publikováno v: Anglican and Episcopal History, 2016 Sep 01. 85(3), 414-416.

Externí odkaz: https://www.jstor.org/stable/43973361

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells (vol 31, pg 1611, 2017)

Autor: Cheadle, E. J., Lipowska-Bhalla, G., Dovedi, S. J., Fagnano, E., Klein, C., Honeychurch, J., Illidge, T. M.

Publikováno v: Cheadle, E J, Lipowska-Bhalla, G, Dovedi, S J, Fagnano, E, Klein, C, Honeychurch, J & Illidge, T M 2017, ' A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells (vol 31, pg 1611, 2017) ' Leukemia, vol 31, no. 10, pp. 2278-2278 . DOI: 10.1038/leu.2016.352
Cheadle, E J, Lipowska-Bhalla, G, Dovedi, S J, Fagnano, E, Klein, C, Honeychurch, J & Illidge, T M 2017, ' A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells (vol 31, pg 1611, 2017) ', Leukemia, vol. 31, no. 10, pp. 2278-2278 . https://doi.org/10.1038/leu.2016.352

Anti-CD20 monoclonal antibodies (mAb) such as rituximab have been proven to be highly effective at improving outcome in B-cell malignancies. However, many patients ultimately relapse and become refractory to treatment. The glycoengineered anti-CD20 m

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::c1346ea34ddd57b017f69a04f796678f
https://doi.org/10.1038/leu.2016.352

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.